Does the media refer more to GLUE or DYN?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 10 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.46 beat Monte Rosa Therapeutics' score of 1.15 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EWTX or GLUE?

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.20 beat Monte Rosa Therapeutics' score of 1.15 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, GLUE or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Monte Rosa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monte Rosa Therapeutics $123.67M 9.92 -$38.63M -$1.76 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media refer more to GLUE or PBLS?

In the previous week, Monte Rosa Therapeutics had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 6 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 1.43 beat Monte Rosa Therapeutics' score of 1.15 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CELC or GLUE?

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 8 mentions for Celcuity. Celcuity's average media sentiment score of 1.26 beat Monte Rosa Therapeutics' score of 1.15 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GLUE or AMLX?

In the previous week, Monte Rosa Therapeutics had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.31 beat Monte Rosa Therapeutics' score of 1.15 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monte Rosa Therapeutics (GLUE) Competitors

$14.38 +0.16 (+1.13%)

As of 04:00 PM Eastern

Compare

GLUE vs. DYN, EWTX, PBLS, CELC, and AMLX

Should you buy Monte Rosa Therapeutics stock or one of its competitors? Monte Rosa Therapeutics's main competitors and comparable companies include Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Parabilis Medicines (PBLS), Celcuity (CELC), and Amylyx Pharmaceuticals (AMLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monte Rosa Therapeutics compare to Dyne Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Monte Rosa Therapeutics currently has a consensus target price of $28.50, indicating a potential upside of 98.19%. Dyne Therapeutics has a consensus target price of $34.42, indicating a potential upside of 37.94%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Monte Rosa Therapeutics has higher revenue and earnings than Dyne Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Dyne Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Monte Rosa Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 10 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.46 beat Monte Rosa Therapeutics' score of 1.15 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Monte Rosa Therapeutics and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.20 beat Monte Rosa Therapeutics' score of 1.15 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics presently has a consensus target price of $50.33, suggesting a potential upside of 19.98%. Monte Rosa Therapeutics has a consensus target price of $28.50, suggesting a potential upside of 98.19%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Monte Rosa Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Edgewise Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Edgewise Therapeutics' return on equity of -39.01% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Edgewise Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Parabilis Medicines has lower revenue, but higher earnings than Monte Rosa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Parabilis Medicines has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Parabilis Medicines' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Parabilis Medicines	N/A	N/A	N/A

Monte Rosa Therapeutics presently has a consensus price target of $28.50, suggesting a potential upside of 98.19%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 2.25%. Given Monte Rosa Therapeutics' higher probable upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Monte Rosa Therapeutics had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 6 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 1.43 beat Monte Rosa Therapeutics' score of 1.15 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monte Rosa Therapeutics beats Parabilis Medicines on 6 of the 11 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Monte Rosa Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 8 mentions for Celcuity. Celcuity's average media sentiment score of 1.26 beat Monte Rosa Therapeutics' score of 1.15 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celcuity has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Celcuity currently has a consensus target price of $154.55, suggesting a potential upside of 60.27%. Monte Rosa Therapeutics has a consensus target price of $28.50, suggesting a potential upside of 98.19%. Given Monte Rosa Therapeutics' higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Celcuity has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Summary

Monte Rosa Therapeutics beats Celcuity on 11 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Amylyx Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Monte Rosa Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A
Amylyx Pharmaceuticals	$87.37M	43.31	-$144.74M	-$1.43	N/A

Monte Rosa Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Monte Rosa Therapeutics had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.31 beat Monte Rosa Therapeutics' score of 1.15 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics presently has a consensus price target of $28.50, suggesting a potential upside of 98.19%. Amylyx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 7.48%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Amylyx Pharmaceuticals beats Monte Rosa Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLUE vs. The Competition

Export

Metric	Monte Rosa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.21B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-8.17	12.66	273.28	25.38
Price / Sales	9.92	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.52	16.29	12.89	6.14
Net Income	-$38.63M	-$22.72M	$3.47B	$349.01M
7 Day Performance	0.42%	-1.37%	-0.33%	-1.47%
1 Month Performance	-6.50%	11.07%	6.51%	2.47%
1 Year Performance	187.60%	53.71%	25.19%	15.84%

Monte Rosa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLUE Monte Rosa Therapeutics	2.8903 of 5 stars	$14.38 +1.1%	$28.50 +98.2%	+189.0%	$1.21B	$123.67M	N/A	90	Positive News
DYN Dyne Therapeutics	3.6477 of 5 stars	$26.37 +1.5%	$34.42 +30.5%	+86.2%	$4.92B	N/A	N/A	100	News Coverage
EWTX Edgewise Therapeutics	3.408 of 5 stars	$43.40 +0.3%	$50.33 +16.0%	+182.5%	$4.71B	N/A	N/A	60	News Coverage Positive News
PBLS Parabilis Medicines	2.4787 of 5 stars	$39.73 +0.4%	$41.67 +4.9%	N/A	$4.69B	N/A	N/A	N/A
CELC Celcuity	2.7776 of 5 stars	$94.94 +4.8%	$154.55 +62.8%	+79.5%	$4.65B	N/A	N/A	40	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. DYN, EWTX, PBLS, CELC, and AMLX

How does Monte Rosa Therapeutics compare to Dyne Therapeutics?

Summary

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Summary

How does Monte Rosa Therapeutics compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. DYN, EWTX, PBLS, CELC, and AMLX

How does Monte Rosa Therapeutics compare to Dyne Therapeutics?

Do analysts rate GLUE or DYN?

Which has higher earnings and valuation, GLUE or DYN?

Is GLUE or DYN more profitable?

Which has more risk & volatility, GLUE or DYN?

Does the media refer more to GLUE or DYN?

Do institutionals & insiders believe in GLUE or DYN?

Summary

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Does the media refer more to EWTX or GLUE?

Do analysts rate EWTX or GLUE?

Which has stronger earnings and valuation, EWTX or GLUE?

Do institutionals and insiders hold more shares of EWTX or GLUE?

Is EWTX or GLUE more profitable?

Which has more risk and volatility, EWTX or GLUE?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Which has stronger valuation & earnings, GLUE or PBLS?

Do institutionals & insiders hold more shares of GLUE or PBLS?

Is GLUE or PBLS more profitable?

Do analysts prefer GLUE or PBLS?

Does the media refer more to GLUE or PBLS?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Which has better earnings and valuation, CELC or GLUE?

Does the media refer more to CELC or GLUE?

Do institutionals and insiders hold more shares of CELC or GLUE?

Which has more volatility and risk, CELC or GLUE?

Do analysts prefer CELC or GLUE?

Is CELC or GLUE more profitable?

Summary

How does Monte Rosa Therapeutics compare to Amylyx Pharmaceuticals?

Which has better valuation & earnings, GLUE or AMLX?

Which has more volatility and risk, GLUE or AMLX?

Is GLUE or AMLX more profitable?

Do insiders and institutionals have more ownership in GLUE or AMLX?

Does the media favor GLUE or AMLX?

Do analysts recommend GLUE or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools